Development of liquid biopsy for early diagnosis of pancreatic cancer using next generation sequence with molecular barcoding detection.

2021 Fiscal Year Final Research Report

• Project/Area Number: 19K07707
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 50020:Tumor diagnostics and therapeutics-related
• Research Institution: Chiba University
• Principal Investigator: Mikata Rintaro 千葉大学, 大学院医学研究院, 講師 (60596146)
• Co-Investigator(Kenkyū-buntansha): 弘津 陽介 地方独立行政法人山梨県立病院機構山梨県立中央病院(がんセンター局ゲノム解析センター), ゲノム解析センター, チーフ研究員 (10793838)
• Project Period (FY): 2019-04-01 – 2022-03-31
• Keywords: 胆膵癌 / NGS / liquid biopsy

Outline of Final Research Achievements

Blood K-RAS mutations were detected in 7/68 (10.3%) in the patients with pancreatic cancer. Circulating tumor cells (CTCs) were also analyzed in 8 pancreatic cancer patients negative for blood K-RAS mutation, and CTCs were detected in 3 (75%) of Stage II cases and 2 (50%) of Stage IV cases. In the analysis of duodenal fluid, it was difficult to identify specific genetic abnormalities because genetic abnormalities thought to be derived from the gastrointestinal tract were also detected. NGS analysis of bile using the cholangiopancreatic Cancer Panel detected oncogenic mutations in 8/15 (53%) of early-stage cases of malignant biliary stricture (Stage I-II cases), suggesting that blood and bile gene analysis may be useful for early diagnosis for these cancers.

Free Research Field

消化器内科

Academic Significance and Societal Importance of the Research Achievements

本研究では膵癌患者の血液、消化液等を利用しNGSを用いた超高感度システムによる遺伝子解析から早期診断のバイオマーカーを探索する目的である。予定していた十二指腸液のNGS解析は今後の集積が必要だが、血液検体を用いたCTC解析や胆汁を用いたNGS解析により、胆膵癌の早期診断につながりうる研究結果が得られた。難治癌であり早期診断が困難な胆膵癌の予後向上につながる可能性のある意義深い結果が得られたと考える。